Conmed [CNMD] vs QuidelOrtho [QDEL] Detailed Stock Comparison
Conmed
NYSE
Loading...
QuidelOrtho
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Conmed wins in 10 metrics, QuidelOrtho wins in 9 metrics, with 0 ties. Conmed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Conmed | QuidelOrtho | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.40 | -0.80 | QuidelOrtho |
| Price-to-Book Ratio | 1.62 | 0.59 | QuidelOrtho |
| Debt-to-Equity Ratio | 91.26 | 90.01 | QuidelOrtho |
| PEG Ratio | 10.55 | 9.85 | QuidelOrtho |
| EV/EBITDA | 10.90 | 7.73 | QuidelOrtho |
| Profit Margin (TTM) | 9.02% | -12.97% | Conmed |
| Operating Margin (TTM) | 7.27% | 7.03% | Conmed |
| EBITDA Margin (TTM) | 7.27% | 7.03% | Conmed |
| Return on Equity | 12.96% | -11.38% | Conmed |
| Return on Assets (TTM) | 4.14% | 1.12% | Conmed |
| Free Cash Flow (TTM) | $153.88M | $-112.10M | Conmed |
| Dividend Yield | 1.15% | N/A | N/A |
| 1-Year Return | -26.98% | -42.18% | Conmed |
| Price-to-Sales Ratio (TTM) | 1.20 | 0.64 | QuidelOrtho |
| Enterprise Value | $2.43B | $4.33B | QuidelOrtho |
| EV/Revenue Ratio | 1.85 | 1.57 | QuidelOrtho |
| Gross Profit Margin (TTM) | 55.33% | 49.55% | Conmed |
| Revenue per Share (TTM) | $43 | $41 | Conmed |
| Earnings per Share (Diluted) | $3.81 | $-5.23 | Conmed |
| Beta (Stock Volatility) | 1.21 | 0.07 | QuidelOrtho |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Conmed vs QuidelOrtho Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Conmed | -0.30% | -0.10% | -3.73% | 2.10% | -29.24% | -25.55% |
| QuidelOrtho | -4.52% | -8.68% | -15.72% | -12.59% | -43.72% | -46.07% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Conmed | -26.98% | -48.31% | -40.99% | -10.78% | 155.82% | 72.60% |
| QuidelOrtho | -42.18% | -73.66% | -91.09% | 17.86% | 89.47% | 241.63% |
Performance & Financial Health Analysis: Conmed vs QuidelOrtho
| Metric | CNMD | QDEL |
|---|---|---|
| Market Information | ||
| Market Cap | $1.58B | $1.76B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 466,651 | 1,485,460 |
| 90 Day Avg. Volume | 444,520 | 1,619,447 |
| Last Close | $50.14 | $24.29 |
| 52 Week Range | $46.00 - $78.19 | $23.77 - $49.45 |
| % from 52W High | -35.87% | -50.88% |
| All-Time High | $159.11 (Nov 01, 2021) | $306.72 (Aug 03, 2020) |
| % from All-Time High | -68.49% | -92.08% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | -0.03% |
| Quarterly Earnings Growth | -0.69% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | -0.13% |
| Operating Margin (TTM) | 0.07% | 0.07% |
| Return on Equity (TTM) | 0.13% | -0.11% |
| Debt to Equity (MRQ) | 91.26 | 90.01 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $31.61 | $44.40 |
| Cash per Share (MRQ) | $1.15 | $1.89 |
| Operating Cash Flow (TTM) | $179.38M | $149.30M |
| Levered Free Cash Flow (TTM) | $159.07M | $297.44M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.15% | N/A |
| Last 12-Month Dividend | $0.60 | N/A |
Valuation & Enterprise Metrics Analysis: Conmed vs QuidelOrtho
| Metric | CNMD | QDEL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.40 | -0.80 |
| Forward P/E | 10.55 | 9.85 |
| PEG Ratio | 10.55 | 9.85 |
| Price to Sales (TTM) | 1.20 | 0.64 |
| Price to Book (MRQ) | 1.62 | 0.59 |
| Market Capitalization | ||
| Market Capitalization | $1.58B | $1.76B |
| Enterprise Value | $2.43B | $4.33B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.85 | 1.57 |
| Enterprise to EBITDA | 10.90 | 7.73 |
| Risk & Other Metrics | ||
| Beta | 1.21 | 0.07 |
| Book Value per Share (MRQ) | $31.61 | $44.40 |
Financial Statements Comparison: Conmed vs QuidelOrtho
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CNMD | QDEL |
|---|---|---|
| Revenue/Sales | $321.26M | $692.80M |
| Cost of Goods Sold | $143.50M | $349.50M |
| Gross Profit | $177.75M | $343.30M |
| Research & Development | $12.95M | $53.20M |
| Operating Income (EBIT) | $15.96M | $48.70M |
| EBITDA | $34.21M | $154.20M |
| Pre-Tax Income | $7.67M | $-8.80M |
| Income Tax | $1.64M | $3.90M |
| Net Income (Profit) | $6.04M | $-12.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CNMD | QDEL |
|---|---|---|
| Cash & Equivalents | $35.49M | $127.10M |
| Total Current Assets | $639.00M | $1.26B |
| Total Current Liabilities | $283.15M | $1.05B |
| Long-Term Debt | $891.44M | $2.27B |
| Total Shareholders Equity | $977.64M | $3.00B |
| Retained Earnings | $560.13M | $123.10M |
| Property, Plant & Equipment | N/A | $2.35B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CNMD | QDEL |
|---|---|---|
| Operating Cash Flow | $49.72M | $41.90M |
| Capital Expenditures | $-3.78M | $-56.20M |
| Free Cash Flow | $37.76M | $9.40M |
| Debt Repayment | $-180.59M | $-36.00M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CNMD | QDEL |
|---|---|---|
| Shares Short | 2.11M | 6.25M |
| Short Ratio | 4.86 | 3.68 |
| Short % of Float | 0.09% | 0.15% |
| Average Daily Volume (10 Day) | 466,651 | 1,485,460 |
| Average Daily Volume (90 Day) | 444,520 | 1,619,447 |
| Shares Outstanding | 30.90M | 67.26M |
| Float Shares | 30.66M | 62.35M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.17% | 1.13% |
Dividend Analysis & Yield Comparison: Conmed vs QuidelOrtho
| Metric | CNMD | QDEL |
|---|---|---|
| Last 12-Month Dividend | $0.60 | N/A |
| Last 12-Month Dividend Yield | 1.15% | N/A |
| 3-Year Avg Annual Dividend | $0.73 | N/A |
| 3-Year Avg Dividend Yield | 0.24% | N/A |
| 3-Year Total Dividends | $2.20 | N/A |
| Ex-Dividend Date | Mar 14, 2025 | N/A |